Category

Press Release

Press Release

Calidi Biotherapeutics Announces The Appointment of Medical Oncologist and Expert in Oncolytic Immunotherapies, Dr. Dmitriy Zamarin to Their Scientific Advisory Board

SAN DIEGO (PRWEB) JUNE 03, 2019 - Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of Dr. Dmitriy Zamarin, MD, Ph.D., to their scientific advisory board. Dr. Zamarin is an accomplished medical oncologist who…
Press Release

Calidi Biotherapeutics Announces The Appointment Of Seasoned Biotech Executive Dr. Ashok Srivastava To Their Scientific Advisory Board

SAN DIEGO, May 30, 2019 /PRNewswire/ -- Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive: Dr. Ashok Srivastava, MD, Ph.D., MBA, to their scientific advisory board. Dr. Srivastava's notable achievements include contributions to…
Press Release

Calidi Biotherapeutics Announces A Collaborative Study With The National Institutes Of Health (NIH) On The Therapeutic Potential Of Oncolytic Viruses Delivered By Mesenchymal Stem Cells

SAN DIEGO, May 28, 2019 /PRNewswire/ -- Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced their ongoing scientific collaboration with David F. Stroncek, M.D., Chief, Cell Therapy Section at the Department of Transfusion Medicine, National Institutes of Health (NIH)…
Press Release

Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

SAN DIEGO, Nov. 6, 2018  -- Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of cell-delivered oncolytic viruses for the treatment of cancer, today announced that data from its clinical studies in late-stage cancer patients will be presented at the Society for Immunotherapy of Cancer…
Calidi Biotherapeutics
November 6, 2018
Press Release

Calidi Biotherapeutics, Inc. Granted New Patent from USPTO for Cell-Based Delivery Of Oncolytic Vaccinia Viruses

SAN DIEGO, October 25, 2018 - Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that it has been granted a new patent from the United States Patent Office (USPTO). Patent Number: 10,105,436 "Smallpox Vaccine for Cancer Treatment" covers the use…
Calidi Biotherapeutics
October 25, 2018